Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Unknown 10Not yet recruiting 3Completed 3Enrolling by invitation 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 6Breast Neoplasms 4Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Locally Advanced Gastric Cancer 2Colorectal Neoplasms 2Cervical Cancer Metastatic 2Triple Negative Breast Neoplasms 1Sarcoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Rare Tumour 1Non-squamous Non-small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Laryngeal Neoplasms 1Esophageal Squamour Cell Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Biliary Tract Neoplasms 1Advanced Triple Negative Breast Cancer 1Advanced Pancreatic Cancer 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × camrelizumab × Clear all
NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Sichuan University

Phase NA Not yet recruiting
98 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06010212 2023-08-24

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡